undamentalytics Newsletter
Sign in

Nasus Pharma Ltd insider trading

Every open-market purchase and sale by Nasus Pharma Ltd's officers, directors and largest shareholders since November 4, 2021, and what the share price did next.

Insider purchases, 5 years $61,809 3 trades by 1 insider Insider sales, 5 years $0 0 trades by 0 insiders
Insider purchase Insider sale Marker size reflects trade value. Weekly closes adjusted for splits; may be delayed.
DateInsiderTrade SharesPriceValue 1M after 3M after 6M after

From insiders' Form 4 filings with the SEC: open-market purchases and sales only (awards, option exercises and shares withheld for tax are excluded), combined to one line per insider per day. "Plan" marks trades the filing says were made under a pre-set Rule 10b5-1 trading plan, which are scheduled in advance. Price changes run from the close on the trade date; hover a figure for the change relative to the S&P 500. Past moves don't predict future ones.

Does following Nasus Pharma Ltd’s insiders pay?

From April 1, 2026 to June 22, 2026, 1 insider reported 3 open-market purchases and 0 sales not made under a pre-set plan in Nasus Pharma Ltd.

InsiderRolePurchases12 months after their purchasesBeat the S&P 500Sales12 months after their salesLatest report
Teleman Dan Benjamin Chief Executive Officer 3 — — 0 — June 22, 2026

Moves are the shares’ return including dividends minus the S&P 500’s, from the close on the first trading day after each report; the number of trades with a finished 12-month window is in brackets. Green means the trade went the insider’s way (a purchase ahead of the index, a sale followed by the shares trailing it). A trade reported both by a director or officer and by a fund or company they are linked to counts once here, under the person. Purchases count only where the share price actually traded was at least $5. These figures describe what the shares did, not why anyone traded. Insiders across all companies.

← Back to Nasus Pharma Ltd · Funds · Politicians